Save up to 90% on Tarlatamab-DLLE with Coupons, Discount Cards & Patient Assistance Programs

Tarlatamab-DLLE is available as a 1 mg or 10 mg single dose vial for IV infusion.

Tarlatamab-DLLE is a bispecific delta-like ligand 3 (DLL3)-directed CD3 Tcell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Tarlatamab-DLLE is a monoclonal antibody that works by helping your immune system slow or stop the spread of cancer cells.

Tarlatamab-DLLE is given as a 1 hr IV infusion by a healthcare provider.

Tarlatamab-DLLE is a safe and effective treatment when used for FDA approved indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Tarlatamab-DLLE: Bone pain, Change in taste, Constipation Loss of appetite, Muscle pain, Nausea

Serious side effects are rare with Tarlatamab-DLLE. Contact your healthcare provider immediately if you experience any of the following: Allergic reactions: skin rash, itching, hives, swelling of the face, lips, tongue, or throat Cytokine release syndrome: fever, chills, unusual weakness or fatigue, loss of appetite, nausea, headache, dizziness, feeling faint or lightheaded, shortness of breath, and fast or irregular heartbeat Infection: fever, chills, cough, sore throat, wounds that don’t heal, pain or trouble when passing urine, general feeling of discomfort or being unwell Liver injury: right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue Low red blood cell level: unusual weakness or fatigue, dizziness, headache, trouble breathing Unusual bruising or bleeding

There are no drug interactions listed for Tarlatamab-DLLE.

Various FDA-approved generic manufacturers

Tarlatamab-DLLE may harm your unborn baby. You should use an effective form of birth control (contraception) during treatment with Tarlatamab-DLLE, and for 2 months after your last dose. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with Tarlatamab-DLLE.

• Imdelltra